

*Circulation* 96:3647–3654, 1997 (subsequently referred to as the “*Circulation* paper”) as representing changes in intracellular calcium concentration of pulmonary artery cells induced by ryanodine and hypoxia.

VII. Dr. Gelband falsified electrophysiological records by reusing the same current-voltage trace as the response of renal vascular cells exposed for 2 seconds to Angiotensin II (Figure 4C) and to Caffeine (Figure 4B) on p. 124 of the publication Gelband, C.H. & Hume J.R. “[Ca<sup>2+</sup>]; Inhibition of K<sup>+</sup> Channels in Canine Renal Artery. A Novel Mechanism for Agonist-Induced Membrane Depolarization.” *Circulation Research* 77(1):121–130, 1995 (subsequently referred to as the “*Circ. Res.* 1995 paper”).

Dr. Gelband also submitted the falsified data above in Figure 4 in NIH grant application R29 JL52189–01A2.

VIII. Dr. Gelband fabricated laboratory research records for four Western blot experiments during the investigation, withholding from the institution his associate’s notebook from which he had removed four labeled autoradiographic films from separate and different experiments, and using the removed films to fabricate a laboratory notebook containing falsified Western blots, which he provided to UF as evidence that he had conducted the experiments under investigation.

The terms of this Agreement are as follows:

(1) Respondent agreed to exclude himself voluntarily from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” as defined in the debarment regulations at 45 CFR part 76, for a period of ten (10) years, beginning on October 3, 2003.

(2) Respondent agreed to exclude himself voluntarily from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant, for a period of ten (10) years, beginning on October 3, 2003.

(3) Within 30 days of the effective date of this Agreement, Respondent agreed to submit letters of retraction to the following journals concerning the specified data in the listed articles:

A. *Hypertension* 2000 paper #1: Figures 5, 6, and 7 merited retraction. A retraction has been submitted relevant to this paper.

B. *Hypertension* 2000 paper #1: Figure 1A merited retraction. A retraction has been submitted relevant to this paper.

C. *JBC* paper: Figure 2 and Figure 4 merited retraction. It has already been withdrawn.

D. *Hypertension Online* paper: Figure 4A and Figure 3 merited retraction. It has already been withdrawn.

E. *Hypertension* 1999 paper: Figure 3 must be retracted.

F. *PNAS* paper: Figure 4A and 4B must be retracted.

G. *Circ. Res.* 1999 paper: Figure 5A must be retracted.

H. *Circ. Res.* 1995 paper: Figure 4C or 4B must be retracted.

**FOR FURTHER INFORMATION CONTACT:**  
Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (301) 443–5330.

**Chris B. Pascal,**

*Director, Office of Research Integrity.*

[FR Doc. 03–28197 Filed 11–7–03; 8:45 am]

**BILLING CODE 4150–31–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Toxic Substances and Disease Registry

#### The Board of Scientific Counselors (BSC), Agency for Toxic Substances and Disease Registry

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Agency for Toxic Substances and Disease Registry (ATSDR) announces the following subcommittee and committee meetings.

*Name:* Board of Scientific Counselors, ATSDR.

*Times and Dates:* 1 p.m.–5:30 p.m., December 1, 2003; 8:30 a.m.–4:30 p.m., December 2, 2003.

*Place:* Hilton Atlanta Hotel, 255 Courtland Street, NE., Atlanta, Georgia 30303.

*Status:* Open to the public, limited by the available space. The meeting room accommodates approximately 100 people.

*Purpose:* The Board of Scientific Counselors, ATSDR, advises the Secretary, and the Administrator, ATSDR, on ATSDR programs to ensure scientific quality, timeliness, utility, and dissemination of results. Specifically, the Board advises on the adequacy of science in ATSDR-supported research, emerging problems that require scientific investigations, accuracy and currency of the science in ATSDR reports, and program areas to emphasize or de-emphasize. In addition, the Board recommends research programs and conference support for which the Agency awards grants to universities, colleges, research institutions, hospitals, and other public and private organizations.

*Matters To Be Discussed:* The agenda items for the meeting will include, but are not limited to, an update and discussion on the

consolidation of the National Center for Environmental Health (NCEH) and the Agency for Toxic Substances and Disease Registry (ATSDR); review of previous discussions for consolidating the Board of Scientific Counselors (BSC) for ATSDR and the Advisory Committee to the Director (ACD) for NCEH; a discussion on peer review background and process; introduction of the next two sessions on peer review; an overview of the National Exposure Registry; discussion of future role of BSC/ACD intramural program reviews, eligible programs for review, and program reviews in 2004; an overview of existing BSC and ACD subcommittees and working groups; review of the Community and Tribal Subcommittee Evaluation Report, Recommendations, and committee membership; discussion of the Social-Behavioral Science Workgroup’s new strategic initiative; and a review of the Health Department Subcommittee on workforce development.

Agenda items are tentative and subject to change.

*Contact Person for More Information:*  
Robert Spengler, Sc.D., Executive Secretary, BSC, ATSDR, M/S E–28, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone 404/498–0003.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and ATSDR.

Dated: November 4, 2003.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 03–28160 Filed 11–7–03; 8:45 am]

**BILLING CODE 4163–70–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2003N–0507]

#### Agency Emergency Processing Request Under OMB Review; Experimental Study of *Trans* Fat Claims on Foods

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for emergency processing under the Paperwork Reduction Act of 1995 (the PRA). The proposed collection of information is an experimental study of *trans* fat claims on foods to evaluate the effects of various possible disclosure requirements to help consumers